Contact
searchSearch
HMP Global
Login
Myelodysplastic Syndromes
Excellence Forum

Myelodysplastic Syndrome Excellence Forum

Rami Komrokji, MD
Conference Coverage
Risk Stratification and Treatment Strategies for High-Risk Myelodysplastic Syndromes
03/05/2025
At the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium, Rami Komrokji, MD discusses the latest updates in risk classification, standard of care, and treatment strategies for myelodysplastic syndromes.
At the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium, Rami Komrokji, MD discusses the latest updates in risk classification, standard of care, and treatment strategies for myelodysplastic syndromes.
At the 2025 Lymphoma, Leukemia &...
03/05/2025
Oncology
Guillermo Garcia-Manero, MD
Conference Coverage
Analyzing Management and Treatment Options for Patients With High-Risk MDS
10/08/2024
Guillermo Garcia-Manero, MD
At the 2024 SOHO meeting, Guillermo Garcia-Manero, MD, shared expert insight into treatment options for patients with high-risk myelodysplastic syndrome.
At the 2024 SOHO meeting, Guillermo Garcia-Manero, MD, shared expert insight into treatment options for patients with high-risk myelodysplastic syndrome.
At the 2024 SOHO meeting,...
10/08/2024
Oncology
Guillermo Garcia-Manero, MD
Conference Coverage
Examining Current and Upcoming Treatment Options for Patients With Low-Risk MDS
10/04/2024
Guillermo Garcia-Manero, MD
At the 2024 SOHO meeting, Guillermo Garcia-Manero, MD, shared expert insight into treatment options that are available and upcoming for patients with low-risk myelodysplastic syndrome.
At the 2024 SOHO meeting, Guillermo Garcia-Manero, MD, shared expert insight into treatment options that are available and upcoming for patients with low-risk myelodysplastic syndrome.
At the 2024 SOHO meeting,...
10/04/2024
Oncology
Pinkal Desai, MD
Videos
Examining Risk Stratification and Novel Treatment Options for Patients With Low and Intermediate-Risk MDS
07/28/2024
Pinkal Desai, MD, discusses risk stratification, restructured disease classifications, and current treatment options for patients with low and intermediate-risk myelodysplastic syndrome at the 2024 Great Debates & Updates meeting.
Pinkal Desai, MD, discusses risk stratification, restructured disease classifications, and current treatment options for patients with low and intermediate-risk myelodysplastic syndrome at the 2024 Great Debates & Updates meeting.
Pinkal Desai, MD, discusses risk...
07/28/2024
Oncology
Aditi Shastri, MD, Montefiore Einstein Comprehensive Cancer Center
Videos
How I Treat: An Elderly Patient With Lower-Risk, Ringed Sideroblastic Negative MDS
07/17/2024
Aditi Shastri, MD, discusses the treatment regimen she chose for an older patient with lower-risk, ringed sideroblastic negative myelodysplastic syndrome.
Aditi Shastri, MD, discusses the treatment regimen she chose for an older patient with lower-risk, ringed sideroblastic negative myelodysplastic syndrome.
Aditi Shastri, MD, discusses the...
07/17/2024
Oncology
Areej El-Jawahri, MD, Massachusetts General Hospital
Conference Coverage
Palliative Care vs Standard of Care in Discussion of End-of-Life Care Preferences for Patients With AML and MDS
06/01/2024

Featuring Areej El-Jawahri, MD

Featuring Areej El-Jawahri, MD ...
Areej El-Jawahri MD, discusses trial results that showed palliative care significantly improved the rates of discussion and documentation of end-of-life care preferences, reduced hospitalization, and improved quality of life for patients with...
Areej El-Jawahri MD, discusses trial results that showed palliative care significantly improved the rates of discussion and documentation of end-of-life care preferences, reduced hospitalization, and improved quality of life for patients with...
Areej El-Jawahri MD, discusses...
06/01/2024
Oncology
Aditi Shastri, MD, Montefiore Einstein Comprehensive Cancer Center
Conference Coverage
Recent Updates in Risk Stratification and Treatment Methods for Patients With MDS
04/10/2024

Featuring Aditi Shastri, MD

Featuring Aditi Shastri, MD
During the 2024 Great Debates & Updates in Hematological Malignancies Meeting, Aditi Shastri, MD, shares expert insight on recent updates in risk stratification and treatment regimens for patients with low to intermediate risk myelodysplastic...
During the 2024 Great Debates & Updates in Hematological Malignancies Meeting, Aditi Shastri, MD, shares expert insight on recent updates in risk stratification and treatment regimens for patients with low to intermediate risk myelodysplastic...
During the 2024 Great Debates &...
04/10/2024
Oncology
Benjamin Tomlinson, MD, Seidman Cancer Center
Videos
How I Treat: A Patient With Myelodysplastic Syndrome With Isolated Deletion of 5q
02/29/2024
Benjamin Tomlinson, MD
Benjamin Tomlinson, MD, explains the course of treatment he selected for a 49-year-old patient with myelodysplastic syndrome with isolated deletion of 5q.
Benjamin Tomlinson, MD, explains the course of treatment he selected for a 49-year-old patient with myelodysplastic syndrome with isolated deletion of 5q.
Benjamin Tomlinson, MD, explains...
02/29/2024
Oncology
Guillermo Garcia-Manero, MD
Videos
Luspatercept vs Epoetin Alfa for Anemia Therapy Among Patients With ESA-Naive, Transfusion-Dependent Lower-Risk MDS
10/10/2023
Guillermo Garcia-Manero, MD
More patients achieved transfusion-independence and an increase in hemoglobin levels with luspatercept versus epoetin alfa, according to data presented at the SOHO 2023 annual meeting by Guillermo Garcia-Manero, MD.
More patients achieved transfusion-independence and an increase in hemoglobin levels with luspatercept versus epoetin alfa, according to data presented at the SOHO 2023 annual meeting by Guillermo Garcia-Manero, MD.
More patients achieved...
10/10/2023
Oncology
Amer Zeidan, MBBS
Videos
New Developments in Risk Stratification and Management of High-Risk and Low-Risk MDS
08/19/2023
Amer Zeidan, MBBS
At the 2023 Great Debates & Updates in Hematologic Malignancies Meeting, Amer Zeidan, MBBS, speaks on recent developments in risk stratification and treatment management among patients with high-risk and low-risk myelodysplastic syndromes.
At the 2023 Great Debates & Updates in Hematologic Malignancies Meeting, Amer Zeidan, MBBS, speaks on recent developments in risk stratification and treatment management among patients with high-risk and low-risk myelodysplastic syndromes.
At the 2023 Great Debates &...
08/19/2023
Oncology

Recent News

News
Modakafusp Alfa Demonstrates Antitumor Activity Among Patients With Relapsed/Refractory Multiple Myeloma
04/02/2025
Emily Estrada
At a tolerable and safe dose, the anti-CD38 antibody, modakafusp alfa demonstrated decreased tumor activity and immune activation among patients with relapsed/refractory multiple myeloma.
At a tolerable and safe dose, the anti-CD38 antibody, modakafusp alfa demonstrated decreased tumor activity and immune activation among patients with relapsed/refractory multiple myeloma.
At a tolerable and safe dose,...
04/02/2025
Oncology
News
Quadruplet Therapy Demonstrates Efficacy for Treatment of Transplant-Ineligible Newly Diagnosed Multiple Myeloma
04/02/2025
Emily Estrada
Quadruplet therapy with isatuximab, weekly bortezomib, lenalidomide, and limited dexamethasone demonstrated safety and efficacy for older patients with transplant-ineligible MM in a phase 2 clinical trial.
Quadruplet therapy with isatuximab, weekly bortezomib, lenalidomide, and limited dexamethasone demonstrated safety and efficacy for older patients with transplant-ineligible MM in a phase 2 clinical trial.
Quadruplet therapy with...
04/02/2025
Oncology
News
Co-Occurrence of High-Risk Cytogenetic Abnormalities as a Predictive Marker for Multiple Myeloma
04/02/2025
Emily Estrada
The presence of 2 or more high-risk cytogenetic abnormalities among patients with multiple myeloma was associated with poor survival outcomes, according to a systematic review and meta-analysis.
The presence of 2 or more high-risk cytogenetic abnormalities among patients with multiple myeloma was associated with poor survival outcomes, according to a systematic review and meta-analysis.
The presence of 2 or more...
04/02/2025
Oncology
News
Pembrolizumab Plus Bevacizumab Shows Promise Among Previously Untreated Patients With Melanoma Brain Metastases
04/01/2025
Stephanie Holland
According to results from a phase 2 study, pembrolizumab plus bevacizumab demonstrated promise among previously untreated patients with melanoma brain metastases.
According to results from a phase 2 study, pembrolizumab plus bevacizumab demonstrated promise among previously untreated patients with melanoma brain metastases.
According to results from a...
04/01/2025
Oncology
News
Outcomes Without Adjuvant Radioactive Iodine Among Pediatric Patients With Papillary Thyroid Cancer
04/01/2025
Allison Casey
According to a retrospective cohort study, omitting adjuvant radioactive iodine therapy for pediatric patients with papillary thyroid cancer did not compromise outcomes.
According to a retrospective cohort study, omitting adjuvant radioactive iodine therapy for pediatric patients with papillary thyroid cancer did not compromise outcomes.
According to a retrospective...
04/01/2025
Oncology
News
Lenvatinib Plus High-Dose Radioiodine Therapy Shows Promise for Patients With Metastatic Well-Differentiated Thyroid Cancer
04/01/2025
Allison Casey
A study found the addition of lenvatinib to high-dose radioiodine therapy showed promise in improving response for patients with metastatic well-differentiated radioiodine-avid thyroid cancer.
A study found the addition of lenvatinib to high-dose radioiodine therapy showed promise in improving response for patients with metastatic well-differentiated radioiodine-avid thyroid cancer.
A study found the addition of...
04/01/2025
Oncology
News
Zenocutuzumab Demonstrates Durable Activity in NRG1 Fusion–Positive Solid Tumors
03/31/2025
Janelle Bradley
Findings from a phase 2 study show zenocutuzumab demonstrated durable clinical activity and a favorable safety profile in patients with NRG1 fusion–positive solid tumors, particularly non–small-cell lung and pancreatic cancers.
Findings from a phase 2 study show zenocutuzumab demonstrated durable clinical activity and a favorable safety profile in patients with NRG1 fusion–positive solid tumors, particularly non–small-cell lung and pancreatic cancers.
Findings from a phase 2 study...
03/31/2025
Oncology
FDA Approval
Durvalumab Approved for Muscle Invasive Bladder Cancer
03/31/2025
Allison Casey
The US FDA approved neoadjuvant durvalumab plus gemcitabine-cisplatin followed by adjuvant durvalumab after radical cystectomy for patients with muscle invasive bladder cancer.
The US FDA approved neoadjuvant durvalumab plus gemcitabine-cisplatin followed by adjuvant durvalumab after radical cystectomy for patients with muscle invasive bladder cancer.
The US FDA approved neoadjuvant...
03/31/2025
Oncology
FDA Approval
FDA Expands Approval of Lutetium Lu 177 Vipivotide Tetraxetan for Metastatic Castration-Resistant Prostate Cancer
03/28/2025
Stephanie Holland
Based on results from the PSMAfore trial, the FDA has expanded the approval of lutetium Lu 177 vipivotide tetraxetan to include patients with PSMA-positive metastatic castration-resistant prostate cancer previously treated with ARPIs and...
Based on results from the PSMAfore trial, the FDA has expanded the approval of lutetium Lu 177 vipivotide tetraxetan to include patients with PSMA-positive metastatic castration-resistant prostate cancer previously treated with ARPIs and...
Based on results from the...
03/28/2025
Oncology
FDA Approval
FDA Approves Cabozantinib for Patients With Locally Advanced or Metastatic Well-Differentiated pNETs and epNETs
03/26/2025
Stephanie Holland
Based on results from the CABINET trial, the FDA has approved cabozantinib for patients 12 years of age and older with unresectable locally advanced or metastatic well-differentiated pNETs and epNETs who experienced disease progression after...
Based on results from the CABINET trial, the FDA has approved cabozantinib for patients 12 years of age and older with unresectable locally advanced or metastatic well-differentiated pNETs and epNETs who experienced disease progression after...
Based on results from the...
03/26/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use